Suppr超能文献

《规则11》对欧洲医疗软件格局的影响:医疗器械法规(MDR)实施三年后对欧洲医疗器械数据库(EUDAMED)及其他数据库的分析

Impact of Rule 11 on the European Medical Software Landscape: Analysis of EUDAMED and Further Databases Three Years After MDR Implementation.

作者信息

Schmitz Arndt A, Font-Nieves Miriam, Doucouré Toumani, Podhaisky Hans-Peter

机构信息

Bayer AG, Pharmaceuticals R&D, Bayer AG, Muellerstr. 178, 13342, Berlin, Germany.

Bayer Hispania, S.L., Regulatory Affairs, Sant Joan Despi, Spain.

出版信息

Ther Innov Regul Sci. 2025 Mar;59(2):365-378. doi: 10.1007/s43441-025-00747-5. Epub 2025 Jan 28.

Abstract

Medicine is increasingly supported by software, with digital health technologies offering innovative ways to capture insights and drive therapies. Globally, medical device software must follow regulatory processes based on risk classification. The introduction of MDR represents a significant shift in risk-based classification for Medical Devices in Europe, including classification Rule 11 for software, which has caused significant discussions among European regulators. Three years after implementation, we conducted a systematic impact assessment of MDR classification Rule 11 for MDSW through a qualitative and quantitative analysis of over 2000 software entries from the European Medical Device database, complemented by data from other public databases such as the German DiGA directory and mHealthBELGIUM. Our results indicate that classification Rule 11 of the MDR results in a narrow bandwidth for class I software, whereas this used to be the most frequent classification for software under the MDD: while most of legacy software in EUDAMED falls in the lowest risk category as MDD Class I (53%), the situation reverses after the implementation of MDR with the most entries in Class IIa (55%). Analyzing the legacy MDD patient apps in Germany implies that three quarters will have to re-classify as MDR Class IIa at the end of the transition period in 2028. A comparison of the European and US regulatory landscapes, along with a systematic review of software features for Class I vs. Class IIa products, explains our findings and enables us to recommend a regulatory strategy for developing MDSW compliant with MDR Class I rules, ensuring fast access to the European market.

摘要

医学越来越依赖软件的支持,数字健康技术提供了获取见解和推动治疗的创新方法。在全球范围内,医疗设备软件必须遵循基于风险分类的监管流程。《医疗器械法规》(MDR)的出台代表了欧洲医疗器械基于风险分类的重大转变,包括软件的分类规则11,这在欧洲监管机构中引发了大量讨论。实施三年后,我们通过对欧洲医疗器械数据库中2000多个软件条目的定性和定量分析,对MDR分类规则11对医疗器械软件(MDSW)的影响进行了系统评估,并辅以来自其他公共数据库的数据,如德国数字医疗应用目录(DiGA)和比利时移动健康(mHealthBELGIUM)。我们的结果表明,MDR的分类规则11导致I类软件的带宽变窄,而在《医疗器械指令》(MDD)下,这曾是软件最常见的分类:虽然EUDAMED中的大多数遗留软件属于MDD I类的最低风险类别(53%),但在MDR实施后情况发生了逆转,IIa类中的条目最多(55%)。对德国遗留的MDD患者应用程序进行分析表明,到2028年过渡期结束时,四分之三的应用程序将不得不重新分类为MDR IIa类。对欧洲和美国监管格局的比较,以及对I类和IIa类产品软件功能的系统审查,解释了我们的发现,并使我们能够推荐一种监管策略,以开发符合MDR I类规则的MDSW,确保快速进入欧洲市场。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验